NCT03723252 (DEAN) is a Phase 3 clinical trial of Dapagliflozin in Nonalcoholic Steatohepatitis, sponsored by Nanfang Hospital, Southern Medical University.

Who is sponsoring NCT03723252?

NCT03723252 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT03723252?

Interventions in NCT03723252: Dapagliflozin, Placebo.

What condition does NCT03723252 study?

NCT03723252 studies Nonalcoholic Steatohepatitis.

Is NCT03723252 still recruiting?

NCT03723252 is currently completed. Last updated 29 March 2024.

Last reviewed 2024-03-29 · How we verify

NCT03723252: DEAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dapagliflozin Efficacy and Action in NASH

Completed Phase 3 Last updated 29 March 2024

What this trial tests

Phase 3 trial testing Dapagliflozin in Nonalcoholic Steatohepatitis in 154 participants. Completed in 28 March 2024.

Timeline

20 March 2019

Primary endpoint
22 March 2024

28 March 2024

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	154
Start date	20 March 2019
Primary completion	22 March 2024
Estimated completion	28 March 2024
Sites	1 location across China

Drugs / interventions tested

Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
Placebo

Conditions studied

Nonalcoholic Steatohepatitis — all drugs for Nonalcoholic Steatohepatitis →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

18 and older, any sex, with Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NAFLD: Mechanisms, Treatments, and Biomarkers.
Nassir F. · · 2022 · cited 245× · PMID 35740949 · DOI 10.3390/biom12060824
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
Xu X, Poulsen KL, Wu L, Liu S, et al · · 2022 · cited 235× · PMID 35963848 · DOI 10.1038/s41392-022-01119-3
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis.
Lee KC, Wu PS, Lin HC. · · 2023 · cited 145× · PMID 36226471 · DOI 10.3350/cmh.2022.0237
An international multidisciplinary consensus statement on MAFLD and the risk of CVD.
Zhou XD, Targher G, Byrne CD, Somers V, et al · · 2023 · cited 134× · PMID 37204656 · DOI 10.1007/s12072-023-10543-8
Metabolic Targets in Nonalcoholic Fatty Liver Disease.
Esler WP, Bence KK. · · 2019 · cited 105× · PMID 31004828 · DOI 10.1016/j.jcmgh.2019.04.007
Metabolic liver disease in diabetes - From mechanisms to clinical trials.
Dewidar B, Kahl S, Pafili K, Roden M. · · 2020 · cited 96× · PMID 32569680 · DOI 10.1016/j.metabol.2020.154299
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P, de la Torre Aláez M, Sangro B, D'Avola D. · · 2023 · cited 91× · PMID 36976456 · DOI 10.1007/s13105-023-00954-4
Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
Fraile JM, Palliyil S, Barelle C, Porter AJ, et al · · 2021 · cited 91× · PMID 34588764 · DOI 10.2147/dddt.s315724

Verify or expand the search:

Other trials of Dapagliflozin

Trials testing the same drug.

NCT07491042 — Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. · NA · recruiting
NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07239011 — Dapagliflozin in Depression · Phase 1, PHASE2 · recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting

Other recruiting trials for Nonalcoholic Steatohepatitis

Currently open trials in the same condition.

NCT07481734 — Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) · Phase 2 · recruiting
NCT06465186 — A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) · Phase 2 · active not recruiting
NCT05526144 — Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans · Phase 2 · recruiting
NCT05330923 — Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease · recruiting
NCT04550481 — Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study · Phase 2 · active not recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03723252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 29 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03723252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing